S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
DIS   132.86 (+1.53%)
Log in

Sanofi Stock Price, News & Analysis (NYSE:SNY)

$46.50
+0.76 (+1.66 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$46.26
Now: $46.50
$46.63
50-Day Range
$42.89
MA: $44.83
$46.60
52-Week Range
$40.00
Now: $46.50
$47.11
Volume824,867 shs
Average Volume1.30 million shs
Market Capitalization$116.44 billion
P/E Ratio14.87
Dividend Yield2.54%
Beta0.67
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone33-1-53-77-44-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$39.60 billion
Cash Flow$5.11 per share
Book Value$26.11 per share

Profitability

Net Income$4.28 billion

Miscellaneous

EmployeesN/A
Outstanding Shares2,504,138,000
Market Cap$116.44 billion
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.


Sanofi (NYSE:SNY) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Tuesday, February 26th. Investors of record on Wednesday, May 8th will be paid a dividend of $1.7395 per share on Friday, May 31st. This represents a yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi SA (NYSE:SNY) posted its earnings results on Monday, July, 29th. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.07. The firm had revenue of $8.63 billion for the quarter, compared to analysts' expectations of $8.42 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company's quarterly revenue was up 5.5% on a year-over-year basis. During the same period last year, the firm earned $1.25 EPS. View Sanofi's Earnings History.

When is Sanofi's next earnings date?

Sanofi is scheduled to release their next quarterly earnings announcement on Thursday, October 31st 2019. View Earnings Estimates for Sanofi.

How can I listen to Sanofi's earnings call?

Sanofi will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Sanofi issued on next quarter's earnings?

Sanofi issued an update on its FY 2019 earnings guidance on Monday, July, 29th. The company provided earnings per share (EPS) guidance of $5.74-5.74 for the period.

What price target have analysts set for SNY?

9 brokers have issued 1-year price targets for Sanofi's stock. Their forecasts range from $50.00 to $52.00. On average, they expect Sanofi's stock price to reach $51.00 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price. View Analyst Price Targets for Sanofi.

What is the consensus analysts' recommendation for Sanofi?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi.

What are Wall Street analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:
  • 1. According to Zacks Investment Research, "Sanofi’s focus on streamlining operations and pursuing business development deals is encouraging. Sanofi’s Specialty Care segment, particularly, is on a strong footing with recent FDA approvals of new drugs Libtayo and Cablivi, and Dupixent for its second indication in asthma. Dupixent could prove to be an important growth driver. The performance of the Vaccines and Consumer Healthcare franchises has also improved of late. Sanofi’s R&D pipeline is strong and it has delivered important results with several positive data read-outs and the achievement of regulatory milestones this year. However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Shares have outperformed the industry in the past six months." (8/29/2019)
  • 2. HC Wainwright analysts commented, "We used a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 7.3% discount rate and 22% effective tax rate. Our assumptions assign a 90% probability of launch to DARZALEX in smoldering MM." (2/28/2019)

Has Sanofi been receiving favorable news coverage?

Media stories about SNY stock have been trending somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Sanofi earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Sanofi.

Who are some of Sanofi's key competitors?

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Johnson & Johnson (JNJ), Gilead Sciences (GILD), AT&T (T), Bank of America (BAC), General Electric (GE), Merck & Co., Inc. (MRK), Exxon Mobil (XOM), AbbVie (ABBV), Alibaba Group (BABA) and Pfizer (PFE).

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:
  • Mr. Olivier Brandicourt, CEO & Director (Age 62)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik, Head of Investor Relations

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Hamlin Capital Management LLC (0.07%), Foundation Resource Management Inc. (0.01%), Cullinan Associates Inc. (0.00%), Beacon Financial Group (0.00%), Pacer Advisors Inc. (0.00%) and Keystone Financial Planning Inc. (0.00%). View Institutional Ownership Trends for Sanofi.

Which institutional investors are selling Sanofi stock?

SNY stock was sold by a variety of institutional investors in the last quarter, including Hamlin Capital Management LLC, Crossmark Global Holdings Inc., CIBC Private Wealth Group LLC, Foundation Resource Management Inc., Stonebridge Capital Management Inc., Commerzbank Aktiengesellschaft FI, Pacer Advisors Inc. and Carroll Financial Associates Inc.. View Insider Buying and Selling for Sanofi.

Which institutional investors are buying Sanofi stock?

SNY stock was acquired by a variety of institutional investors in the last quarter, including Reilly Financial Advisors LLC, Cullinan Associates Inc., Willow Creek Wealth Management Inc., Beacon Financial Group, Old North State Trust LLC, Signaturefd LLC, Keystone Financial Planning Inc. and NewSquare Capital LLC. View Insider Buying and Selling for Sanofi.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $46.50.

How big of a company is Sanofi?

Sanofi has a market capitalization of $116.44 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. View Additional Information About Sanofi.

What is Sanofi's official website?

The official website for Sanofi is http://www.sanofi.com/.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]


MarketBeat Community Rating for Sanofi (NYSE SNY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  434 (Vote Outperform)
Underperform Votes:  541 (Vote Underperform)
Total Votes:  975
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: What are Bollinger Bands?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel